Sleep, Diet, Exercise and Older Persons
High-Speed Circuit Resistance Training vs. High-Speed Multidirectional Yoga on Changes in Cognition in Healthy Older Adults.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Joseph Signorile, PhD
- Phone Number: 305-284-3105
- Email: jsignorile@miami.edu
Study Contact Backup
- Name: Rosalia Parrino, MS
- Phone Number: 305-284-4173
- Email: rxp931@miami.edu
Study Locations
-
-
Florida
-
Coral Gables, Florida, United States, 33147
- Laboratory of Neruomuscular Research and Active Aging
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Montreal Cognitive Assessment > 23
- No memory loss complaints
Exclusion Criteria:
- Uncontrolled cardiovascular or neuromuscular disease that prevents participation in a training program
- Musculoskeletal impairments or injury that may impact exercise participation
- Visual or hearing impairments
- Neurological disease
- Stroke
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: High-Speed Circuit Resistance Training Group
Participants in this group will receive high-speed circuit resistance training for 12 consecutive weeks.
|
three times per week; 45 minutes per session; 12-weeks
|
|
Experimental: High-Speed Multidirectional Yoga Group
Participants in this group will receive high-speed multidirectional yoga for 12 consecutive weeks.
|
two times per week; 60 minutes per session; 12-weeks
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Changes in Executive Function
Time Frame: Baseline, 16 weeks
|
Changes in executive function composite score measured by the NIH Toolbox Cognition Module
|
Baseline, 16 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Changes in Nutritional Status
Time Frame: Baseline, 16 weeks.
|
Nutritional status will be assessed by the Nutritionist Pro (Axxya Systems, Redmond, WA), a nutrition analysis software that can be used for diet 24 hour recalls.
Participants will be asked to recall food intake for one weekday and one weekend day.
|
Baseline, 16 weeks.
|
|
Changes in Sleep Quality as measured by the Pittsburg Sleep Quality Index
Time Frame: Baseline, 16 weeks.
|
The Pittsburg Sleep Quality Index has seven component scores that are added to yield one global score, with a range of 0-21 points, "0" indicating no difficulty and "21" indicating severe difficulties in all areas.
|
Baseline, 16 weeks.
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Joseph Signorile, PhD, University of Miami
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Mental Disorders
- Neurocognitive Disorders
- Cognition Disorders
- Cognitive Dysfunction
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Neurotransmitter Uptake Inhibitors
- Membrane Transport Modulators
- Dopamine Agents
- Dopamine Uptake Inhibitors
- Central Nervous System Stimulants
- Sympathomimetics
- Adrenergic Uptake Inhibitors
- Methamphetamine
Other Study ID Numbers
Other Study ID Numbers
- 20221319
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.